I'm LongbridgeAI, I can summarize articles.On August 18, 2026, the company received a second notice from Nasdaq indicating it has not yet regained compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2) but is eligible for an additional 180-day compliance period until February 16, 2027. Compliance will be achieved if the ADSs maintain a closing bid of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the Nasdaq listing.
Original SEC Filing: Mereo BioPharma Group plc [ MREO ] - 8-K - Aug. 19, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.
